Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. NT-proBNP and ICD in Nonischemic Systolic Heart Failure: Extended Follow-Up of the DANISH Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Reply to left atrial strain: A potential target to predict atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Right ventricular strain predicts adverse outcomes in patients undergoing coronary artery bypass grafting

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

BACKGROUND: The Heart Failure Collaboratory (HFC) has developed a score integrating classes and doses of guideline-directed medical therapies prescribed for patients with heart failure (HF) and reduced ejection fraction. One potential use of this score is to test whether new treatments demonstrate incremental benefits, even in patients receiving comprehensive guideline-directed medical therapy.

OBJECTIVES: The authors investigated the efficacy of dapagliflozin according to a modified HFC score in the DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) trial.

METHODS: In DAPA-HF, 4,744 patients with HF and reduced ejection fraction were randomized to dapagliflozin or placebo. The modified HFC score accounted for race and electrocardiogram rhythm and rate, with a maximum possible score of 100%. The primary outcome was the composite of worsening HF or cardiovascular death.

RESULTS: The median modified HFC score was 50% (IQR: 27.5%-62.5%; range 0%-100%). Compared with the lowest tertile, the highest tertile of the treatment score was associated with a lower risk of worsening HF or cardiovascular death (tertile 1, reference; tertile 2, HR: 0.97 [95% CI: 0.82-1.14]; tertile 3, HR: 0.83 [95% CI: 0.70-0.99]). Dapagliflozin reduced the risk of worsening HF or cardiovascular death, irrespective of treatment score (the HRs for dapagliflozin vs placebo from tertile 1 to 3 were: 0.76 [95% CI: 0.61-0.94], 0.76 [95% CI: 0.60-0.97], and 0.71 [95% CI: 0.55-0.90]), respectively; Pinteraction = 0.89). Consistent benefits were observed for HF hospitalization, cardiovascular death, all-cause mortality, and improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TTS).

CONCLUSIONS: Dapagliflozin, compared with placebo, improved all outcomes examined, regardless of the modified HFC score. This score can be easily calculated in clinical trials and used to evaluate the incremental effects of new treatments. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124).

OriginalsprogEngelsk
TidsskriftJACC. Heart failure
Vol/bind10
Udgave nummer8
Sider (fra-til)543-555
Antal sider13
ISSN2213-1779
DOI
StatusUdgivet - aug. 2022

Bibliografisk note

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

ID: 80000896